Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX StudyAndy C. Rawstron, Roger G. Owen, Walter M. Gregory et al.|Journal of Clinical Oncology|2013Cited by 419
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib ExposureAndy C. Rawstron, Peter Hillmen, Talha Munir et al.|Blood|2018Cited by 7